SCHEMBL23214967

SCHEMBL23214967

Cc1cc(CN2CCC(C(N)c3cc(Cl)c(Cl)cc3OC(=O)C(F)(F)F)CC2)no1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRKAA2 P54646 1/20 0.34
TLR9 Q9NR96 3/20 0.34
TLR8 Q9NR97 3/20 0.34
TLR7 Q9NYK1 3/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GLP1R P43220 1/20 0.32
JAK2 O60674 2/20 0.32
JAK1 P23458 2/20 0.32
ENPP2 Q13822 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
AURKA O14965 2/20 0.32
P2RY12 Q9H244 1/20 0.31
S1PR1 P21453 1/20 0.31
ACKR3 P25106 1/20 0.31
KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL23214969 0.85 PRKAA2 (0.37) PRKAA2TLR9TLR8TLR7KDM4E
SCHEMBL23215569 0.82 CHRM3 (0.42) KCNH2
SCHEMBL23230371 0.81 AURKA (0.37) PRKAA2TLR9TLR8TLR7AURKA
SCHEMBL29745291 0.81 AURKA (0.37) PRKAA2TLR9TLR8TLR7AURKA
SCHEMBL23216733 0.81 DPP4 (0.32) TLR9TLR8TLR7KDM4EALDH1A1
SCHEMBL23215565 0.80 DPP4 (0.33) KCNH2
SCHEMBL23214994 0.80 ACHE (0.40) KCNH2
SCHEMBL23215346 0.77 DPP4 (0.34)
SCHEMBL23216009 0.77 SMYD3 (0.39) ALDH1A1SMN1; SMN2
SCHEMBL23216090 0.77 CPN1 (0.36) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 US disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNH3 PRKAA2 2909/4885TLR9 4801/4885TLR8 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.